Information on medicine consumption available to everyone by Lindgren-Äimänen, Katja & Närhi, Ulla
L Ä Ä K E I N F O R M A A T I O T A  L Ä Ä K E L A I T O K S E L T A
LÄKEMEDELSINFORMATION FRÅN LÄKEMEDELSVERKET, FINLAND  |  DRUG INFORMATION FROM THE NATIONAL AGENCY FOR MEDICINES, FINLAND 
5 . 2 0 0 1
Lääkekulutustiedot kaikkien käyttöön 5 Masennuslääkkeiden käyt-
tö ahdistuneisuushäiriöissä 6 Galantamiini 9 Levosimendaani 10
Linetsolidi 11 Lääkkeet ja ikenen liikakasvu 13 Ehkäisytablettien
turvallisuutta arvioitu Euroopan lääkearviointivirastossa 16 Tuleh-
TA
BU
LAK0105_I-IVkansilopu  15.10.2001  10:24  Sivu 3
S a m m a n d r a g
Ledare
Katja Lindgren-Äimänen | Ulla Närhi  . . . . . .
Hannu Koponen  . . . . . . . . . . . . . . . . . . . . . .
Om biverkningar
Hellevi Ruokonen  . . . . . . . . . . . . . . . . . . . . .
FPA nyheter
Timo Klaukka | Sinikka Rajaniemi  . . . . . . . .
Ex tempore
S u m m a r y
Editorial
Katja Lindgren-Äimänen | Ulla Närhi  . . . . . .
Hannu Koponen  . . . . . . . . . . . . . . . . . . . . . .
ADR News
Hellevi Ruokonen  . . . . . . . . . . . . . . . . . . . . .
Drug use
Tinna Voipio  . . . . . . . . . . . . . . . . . . . . . . . . .
28
29
32
35
37
37
38
39
42
45
49
Information om läkemedelskonsumtion tillgänglig för alla
Användning av antidepressiva vid ångeststörningar
Läkemedel och gingival hyperplasi
Specialersättning har inte påskyndat ökningen av statin-
användningen 
Införsel från utlandet av läkemedelspreparat som 
innehåller metadon för personlig medicinering
Spelregel för elekroniska recept
Information on medicine consumption available to everyone
Antidepressants used in anxiety disorders
Drugs and gingival overgrowth
Consumption of anti-inflammatory analgesics: the effect of
the switch to OTC 
Lääkelaitoksen päätöksiä
5.2001
9. vuosikerta
9 årgången
9th Annual volume
LAK0105_03-04 sisältö  15.10.2001  10:35  Sivu 4
38 TABU 5.2001
Information on medicines and medicine consumption is
widely needed in society. There is a demand especially
for unbiased and objective information, which the Na-
tional Agency for Medicines has at its disposal. Collect-
ing the latest information on the sales and consumption
of medicines, and knowing the current trends in the
pharmaceutical field, are closely linked with monitoring
the safety of medicines.
The National Agency for Medicines wants to pro-
vide the latest information on medicines more openly
than before. Openness, flexibility, interactivity and ac-
tivity in communications are also part of the govern-
ment communication policy, as recommended last spring
by the Working Group on Governmental Communica-
tion in the 2000s.
In October, the National Agency for Medicines will
start publishing on Internet pages (www.nam.fi) medi-
cine consumption statistics based on the data in the
Register of Medicine Sales. Annual medicine consump-
tion statistics have been published since 1987 jointly by
the National Agency for Medicines and the Social Insur-
ance Institution under the title Finnish Statistics on
Medicines. The electronic version of consumption fig-
ures for the year 2000 will complement the printed vol-
ume. Both versions will be published in October.
The data in the Register of Medicine Sales is based
on the monthly sales figures reported by pharmaceutical
wholesalers. The medicine consumption by each therapy
group is monitored on the basis of this data. Medicine
consumption is expressed in terms of defined daily doses
(DDD/1,000 inh. /day). Defined daily dose is an interna-
tionally used term for the consumption of medicines,
where the quantities of medicines sold are converted to
a figure expressing the defined daily dose relative to
1,000 inhabitants per the total population per day.
Medicines are categorised according to the anatomic-
therapeutic-chemical (ATC) classification system. 
At first, the medicine consumption statistics pub-
lished on the Internet will be the same as those pub-
lished in the printed format. The charts will include the
annual statistics for 1999 and 2000. Medicine consump-
tion statistics will also be represented graphically based
on selected charts. 
In the future, our objective is to develop a user-
friendlier package by facilitating the search for informa-
tion further. When compiling statistics, we can also
make use of regional consumption figures, and data on
medicine consumption in earlier years. By monitoring
the medicine sales patterns, we can draw conclusions on
changes in medicine prescription practices and assess the
rationale behind such changes. We would welcome any
feedback on the publication of medicine consumption
statistics, and suggestions for improvement. Please send
your suggestions by e-mail to: salesstatistics@nam.fi.
The rearranging of the National Agency for Medi-
cines’ web site has begun. In the course of the autumn
we will classify the web pages according to various in-
terest groups, and create information service packages
catering for their needs. We can then use this active
communications channel as a medium for publishing
news and current affairs. In the future, we plan to sup-
ply even more information on medicines and on the ac-
tivities of the National Agency for Medicines on our re-
newed web site.
The Scandinavian countries supply similar data on
medicine consumption at the following Internet address-
es:
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Denmark:http: / /www.dkma.dk
Iceland:http:/ /brunnur.st j r . is / interpro/htr /htr .nsf /
pages/ lyf janotkun-1989-1999 
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Normal anxiety signals a threat and
serves as encouragement to a person
to cope with the impending situation
on his/her own. Anxiety also promo-
tes the feeling of togetherness and
improves emotional ties between in-
dividuals, thereby helping the com-
munity to cope better. Anxiety may
be considered exceptional if its dura-
tion or degree of severity is unbal-
anced in relation to the threat caus-
ing the anxiety or if the anxiety oc-
curs without a triggering factor. Anx-
iety disorders (Table 1) are the com-
monest of the psychiatric disorders,
occurring in at least 7–10% of Finns
according to earlier reports (Lehtinen
et al. 1990), though even higher fre-
quencies of over 15% in western
countries have been reported (e.g.
Kessler at al. 1994). Anxiety disor-
ders are associated with a significant
reduction in ability to function, re-
duced ability to work and concurrent
illnesses such as depression.
Causes of exceptional anxiety
have been thought to consist of in-
ternal mental conflicts, unusual con-
ditioning, or disturbances in the cog-
nitive treatment of emotional states.
According to recent studies, besides
factors associated with the growing
environment, genetic factors also
play a role (Kendler et al. 2001).
From the point of view of neurobiol-
ogy, anxiety is a state which is devel-
oped jointly  through the brainstem,
the limbic system, prefrontal areas of
the cerebral cortex and the cerebel-
lum. The nuclei of the brainstem, e.g.
the locus coeruleus, take part  in the
control of alertness, whereas the lim-
bic system controls the physiological
and emotional responses associated
with the threat factors. The hippo-
campus and amygdala also play an
important role in the control of the
content of memory associated with
emotional states. The prefrontal ar-
eas control the management of ac-
tion and decisionmaking. These
functions are mediated via several
neurotransmitters such as gamma-
aminobutyric acid, noradrenaline,
serotonin and corticotropin-releasing
hormone, which offers the opportu-
nity for medical interference with the
activity of nerve networks important
in the development of anxiety disor-
ders (Noyes and Hoehn-Saric 1998).
The serotonin pathways start
from a nucleus in the median raphe
of the medulla and continues to the
limbic and nigrostriatal area and the
cerebral cortex.  At least 14 different
serotonin receptors have been detect-
ed with certainty, and consequently
the effects of the serotonergic net-
work on anxiety are varied and part-
ly also conflicting. The serotonin sys-
tem reduces the prefrontal cerebral
cortex activity and stabilises alertness
by its effect on the locus coeruleus.
These effects reduce anxiety and ex-
plain the anxiety-removing effect of
drugs with an influence on the sero-
tonin system (Shelton and Brown
2001). Antidepressants may also
have beneficial neuroprotective ef-
fects (Raid and Stewart 2001).
Anti-anxiety drugs  
Ethanol, bromides, paraldehyde, bar-
biturates and meprobamate have pre-
viously been used for anxiety and
sleep disturbances with varied suc-
cess.  Their use was, however, associ-
ated with considerable problems of
dosage, toxic effects and drug depen-
dence, and consequently the benzodi-
azepines developed at the end of the
1950s rapidly attained an important
position in the treatment of anxiety
disorders. In some patients, and es-
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Antidepressants used in anxiety disorders
Summary 
Anxiety disorders are common psychiatric disorders often of long duration, with a significant ef-
fect on the patient’s ability to function and the quality of life of the sufferers.  They are also asso-
ciated with a considerable risk of concurrent illnesses such as severe depression and drug/alcohol
abuse.  During the last decade, a lot of new information which can be applied in clinical practice
has emerged regarding the medical treatment of anxiety disorders.  The following survey discusses
the biological background of anxiety disorders and the possibilities of medical treatment of panic
disorders, social phobia, obsessive-compulsive disorders and generalised anxiety disorders.
Table 1.  Neurotic  somatoform dis-
orders associated with stress (Dis-
ease classification ICD-10 1997)
• phobic anxiety disorders
- agoraphobia
- social phobia
- defined (individual) fears
• other anxiety disorders
- panic disorder
- generalised anxiety disorder
- mixed anxiety disorder and 
depression
- obsessive-compulsive disorder
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pecially on long-term use, they are,
however, associated with problems
of dependence, tolerance and the ne-
cessity of increasing the dose; which
is why other psychotropic drugs
(traditional antipsychotics and tri-
cyclic antidepressants previously,
and more recent antidepressants to
an increasing degree since the begin-
ning of the 1990s) have been used in
long-term treatment of anxiety dis-
orders (Lepola 1999). New groups
of drugs to treat anxiety disorders
are also under development which,
in their mechanism of action, differ
from the foregoing. 
Antidepressants in anxiety 
disorders
Among antidepressants imipramine,
for instance, has been used since as
early as the 1960s in long-term
treatment of anxiety disorders such
as panic disorder. However, antide-
pressants mainly affecting the sero-
tonergic activity and introduced on
to the market at the turn of the
decade of 1980/1990 and new two-
channel antidepressants introduced
into use after the mid 1990s, have
widened their use in the treatment
of anxiety disorders, partly due to
the improved tolerability of new
molecules.
The efficacy of antidepressants is
based on their regular use and it
may take several months until any
response emerges (Table 2). When
antidepressants are used to treat
anxiety disorders, the treatment
should usually be started with a
small initial dose and the dose
should thereafter be increased slow-
ly to avoid adverse effects in the ini-
tial stages. The therapeutic doses
used are nevertheless similar to
those used in the treatment of de-
pression (Leinonen et al. 2000).
Treatment of anxiety disorders is of-
ten long-term, but there are very few
studies of the time scales used in the
treatment. Clinical experience has
shown, however, that a minimum
6–12 months of treatment is re-
quired in most anxiety disorders.
Adverse effects associated with the
use of antidepressants, the most
common of which are initial nausea,
and sexual adverse effects and in-
creased sweating on longer term use,
have not usually obstructed the
treatment, and this is especially im-
portant in disorders requiring long-
term treatment. Towards the end of
the medical treatment, gradual with-
drawal of medication is often advis-
able (Michelson et al. 2000).
Generalised anxiety
The important symptoms of gener-
alised anxiety include anxiety, exces-
sive care and various somatic symp-
toms associated with these. Its life-
long prevalence is on average 5–6%
and it is often associated with other
concurrent psychiatric disturbances
such as depression and drug abuse.
As a disturbance of  long duration,
it usually has a significant adverse
effect on the ability to function. The
number of drug trials in generalised
anxiety is smaller than that in other
anxiety disorders, but in studies
with paroxetine and venlafaxine, for
instance, the initial signs of the ef-
fect of treatment have been visible
within 2–3 weeks and the response
has improved with higher doses (All-
gulander et al. 2001).
Panic disorder
Panic disorder is characterised by se-
vere mental attacks of anxiety
which, besides various somatic
symptoms, are also associated with
a fear of death or a fear of losing
control and becoming insane.  Panic
disorders may occur spontaneously
or they may be associated with vari-
ous situations.  The life-long preva-
lence of panic disorders is estimated
at about 3% (Academy of Finland
2000).  They are also associated
with a considerable risk of depres-
sion when the patient’s symptoms
worsen, and concurrent depression
is also associated with a higher risk
of suicide and a more severe reduc-
tion in the quality of life (Roy-Byrne
et al. 2000).
Previously, panic disorders were
often treated with benzodiazepines,
but the primary medical treatment
for panic disorders nowadays con-
sists of selective serotonin re-uptake
inhibitors. The efficacy of all sero-
tonin selective antidepressants in use
Table 2.  A comparison of  propert ies of  benzodiazepines,  buspirone and antidepressants.
Benzodiazepines Buspirone Antidepressants
Single dose is effective Yes Yes No
Time before the start of 
complete response Days Weeks Weeks
Tiredness Yes No No
Risk of dependence Yes No No
Impairs performance Yes No No
Decreases withdrawal symptoms Yes No No
Dosage once a day No No Yes
Efficacy in concurrent depression No No Yes
Most common adverse effects Tiredness, Anxiety, Gastrointestinal
memory nervousness symptoms,
disturbances disturbances of
sexual function 
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in Finland is documented in the
treatment of panic disorders. Initial-
ly, a small dose should be used
which is then increased to the thera-
peutic dose within a couple of
weeks. A response to treatment is
usually obtained within 3–6 weeks
of treatment and the treatment
should be continued for at least
6–12 months after recovery (Lepola
et al. 1998).
Social phobia
Social phobia is the most common
anxiety disorder occurring in the
general public. Epidemiological
studies have found its prevalence to
be around 4–8%, and symptoms oc-
curring in most situations associated
with performance and interaction
have an especially significant ad-
verse effect on education, work and
quality of life (Stein et al. 2000).
New antidepressants and behaviour-
al therapy are also beneficial in the
treatment of social phobia, and the
combined use of these forms of
treatment is recommended at least
for the most severe symptoms (Blom-
hoff et al. 2001). The use of antide-
pressants in long-term treatment of
social phobia is also supported by
the risk of depression associated
with this disorder. Bouts of depres-
sion occur in about a half of these
patients, and social phobia in ado-
lescents or young adults is consid-
ered to be a risk factor for bouts of
depression later in life (Stein et al.
2001).
Obsessive-compulsive disorder 
Obsessive-compulsive disorder was
previously considered rare, but epi-
demiological studies have changed
the estimate of its prevalence be-
cause 1–2.5% of the adult popula-
tion suffers from this type of anxiety
disorder.  Even though few people
recover totally  with treatment, the
aim of treatment is to diminish the
occurrence of symptoms and ad-
verse effects on the daily life. The
symptoms of patients who benefit
from treatment are usually reduced
by 30–70%, and the treatment of
patients with a positive response
should be continued for at least one
year, often even longer. A significant
risk of depression is associated with
obsessive-compulsive disorder, and
about 60% of patients suffer from
severe depression at some stage of
their lives.  Antidepressants based
on serotonin re-uptake inhibition
are effective in the treatment of ob-
sessive-compulsive disorder, and the
doses used are often at the upper
end of the dosage scale (Koponen et
al. 1997). Patients with obsessive-
compulsive disorder do not, howev-
er, benefit from benzodiazepines or
antipsychotics. Antidepressants are
an effective alternative also for pa-
tients who suffer from depression in
addition to obsessive-compulsive
disorder (Hoehn-Saric et al. 2000).
Conclusion
Anxiety disorders are common and
they are associated with significant
adverse effects in the form of sub-
jective suffering, reduced capacity
for work and other concurrent dis-
abilities. For the treatment of anxi-
ety disorders of long duration, the
aim has been to develop forms of
treatment with improved tolerability
and without associated dependence-
forming tendencies, examples of
which are the use of serotoninselec-
tive and new two-channel antide-
pressants in different anxiety disor-
ders.  In the treatment of anxiety of
short duration, benzodiazepines still
offer the most commonly used
choice of medical treatment, even
though drugs with similar effects
but without the associated adverse
effects are continuously being devel-
oped.
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Summary 
Two of the most important drugs
with gingival overgrowth (gingival
hyperplasia) are ciclosporin (1), and
calcium channel blockers (2,3).
Phenytoin has also been reported to
have caused gingival overgrowth (4),
(Table). Phenytoin-induced gingival
overgrowth is, however, seen by a
dentist less frequently nowadays as
other drugs are also used for the
treatment of epilepsy today.
The term gingival hyperplasia
has been used hitherto in the litera-
ture for gingival overgrowth. Gingi-
val hyperplasia denotes a condition
where the number of cells in the tis-
sue is increased. From a histological
point of view, the number of fibro-
blasts in drug-induced gingival over-
growth is not increased significantly,
but the amount of collagen and in-
tercellular material produced by
them is, probably due to the reduced
rate of metabolism (5,6). Conse-
quently, the English literature nowa-
days most often uses the term gingi-
val overgrowth or gingival enlarge-
ment rather than gingival hyperpla-
sia.
Gingival overgrowth hinders the
daily cleaning of the teeth and caus-
es plaque accumulation, and may
thereby perpetuate gingivitis. On the
other hand, the development of
overgrowth is encouraged by gin-
givitis associated with poor oral hy-
giene or by periodontitis, an infec-
tion which has advanced further to
the periodontium of the teeth. Gin-
gival overgrowth often starts in the
interdental spaces and is usually
more prominent on the labial sur-
faces of the teeth than on the palatal
or lingual surfaces. In severe cases
the overgrowth is generalised in the
entire dental area and may be ex-
tended as far as the occlusal surface
of the teeth, interfering with chew-
ing (Fig. 1 a and b). Gingival over-
growth is often a functional as well
as a cosmetic impediment. In associ-
ation with ciclosporine, the possible
development of malignancies should
also be considered; squamous cell
carcinoma and Kaposi’s sarcoma
have been reported in the literature
(7,8).  Overgrowth should conse-
quently be removed surgically and a
tissue sample taken for histological
examination (9).
Ciclosporin
Ciclosporin is an immunosuppres-
sive agent which is used to prevent
organ rejection in kidney, liver,
heart, heart/lung, lung or pancreas
transplantation. It is also used in
bone marrow transplantations both
for the prevention and treatment of
graft-versus-host disease (GVHD).
Other indications for ciclosporin 
include rheumatoid arthritis, neph-
rotic syndrome, endogenous uveitis,
severe psoriasis and severe atopic
dermatitis (10,11).
Ciclosporin is a cyclic polypep-
tide consisting of 11 amino acids.  It
prevents the development of cell-me-
diated reactions by inhibiting T-cell
proliferation. At the cell level, ciclo-
sporin prevents the generation and
release of lymphokines, including in-
terleukin-2. Ciclosporin inhibits T-
Drugs and gingival overgrowth
Hellevi Ruokonen
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Drugs,  which may cause gingival  overgrowth
• Ciclosporin Sandimmun 
• Calcium channel blockers
Diltiazem Cardizem, Dilmin, Dilpral, Dilzem, Viazem
Verapramil Chronovera, Isoptin, Vermin, Verpacor, Verpamil
Dihydropyridine derivatives
- amlodipine Norvasc
- felodipine Hydac, Plendil
- isradipine Lomir
- lercanidipine Zanidip       
- nifedipine Adalat,  Nifangin, Nifdemin, Nifecor
- nisoldipine Syscor
- nilvadipine Escor
• Phenytoin Hydantin
A D R  N e w s
Fig. 1 a and b. A heart transplant patient on combined ciclosporin and calcium
channel blocker therapy.  The patient had pronounced  gingival overgrowth which
was surgically removed. a = prior to treatment, b = after treatment.
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cell activation at the start of the cell
cycle by preventing the release of
lymphokines.  It has a less impor-
tant effect on B-cell activity and it
does not interfere with haemato-
poiesis or influence the phagocyte
activity (10, 12,13).
Gingival overgrowth was report-
ed for the first time  in the literature
in 1983 (1). The prevalence of over-
growth in organ transplant patients
varies considerably according to dif-
ferent studies (8%–70%), most like-
ly due to the variety of patient
groups (11,14).  The prevalence in
children has been reported to be as
high as 80% (15,16).  Fibrotic,
thickened gums in children may pre-
vent the normal eruption of perma-
nent teeth (Fig. 2 a and b). There
are no reports in the literature of
overgrowth caused by ciclosporin in
edentulous areas.
Overgrowth typically begins at
the gingival papillae. Overgrown ex-
cessive tissue must often be removed
surgically before maintenance of the
patient’s normal oral hygiene is even
possible (Fig. 3 a and b).
Calcium channel blockers
The first case of gingival overgrowth
developed as an adverse effect of
calcium channel blockers was asso-
ciated with nifedipine and was re-
ported in 1984 (2). Gingival over-
growth has also been reported of ve-
rapamil (3), amlodipine (17),
felodipine (18) and diltiazem (19).
Gingival overgrowth caused by cal-
cium channel blockers is clinically
similar to that caused by ciclo-
sporine or phenytoin, see Fig. 4 a
and b.
Calcium channel blockers are of-
ten used for the treatment of hyper-
tension in kidney transplant pa-
tients.  Kidney transplant patients
receiving nifedipine in addition to ci-
closporine have a higher risk of de-
veloping overgrowth (9,20). Accord-
ing to one study, the extent and
severity of overgrowth is significant-
ly related to the plasma concentra-
tion of ciclosporine (21). 
Phenytoin
Gingival overgrowth caused by
phenytoin was reported for the first
time in medical literature over 60
years ago (4).  Studies have shown a
correlation between the gingival
overgrowth caused by bacterial
plaques and dental calculus and that
caused  by phenytoin (22,23). Gingi-
val overgrowth typically starts from
gingival papillae and is often lo-
calised to the area of the front teeth.
Overgrowth can occur in the entire
dental area. Overgrowth caused by
phenytoin has also been reported in
edentulous patients (24).
Treatment
Treatment of gingival overgrowth
consists of its surgical removal.  The
overgrowth can be removed by gin-
givectomy or periodontal flap
surgery (25).  In gingivectomy, the
surface of the wound is often treated
with a CO2 laser.  The benefits of
the use of a CO2 laser are: good
haemostasis, reduced  postoperative
pain and swelling, and a sterilising
effect on the wound surface.  The
patient should be provided with a
total dental treatment plan which
would include the extraction of
teeth with poor prognosis and the
planning of basic periodontal treat-
ment with associated removal of
overhanging margins of fillings and
crowns and dental calculus and in-
struction of the patient in a correct
dental cleaning technique.  Changes
caused by plaque-retaining caries
should be treated with fillings.
Prevention of overgrowth includes
careful dental care at home and pro-
fessional cleaning of teeth carried
out by a dentist or a specialised den-
Fig. 2 a and b. A 7-year-old kidney transplant patient on ciclosporin thera-
py.  The gingival tissue in the upper front dental area is thickened by fibrosis, prevent-
ing the emergence of permanent teeth (a).  The patient had a gingival operation un-
der general anaesthesia, with exposure of  the permanent upper front teeth.   Fig. (b)
2 weeks after the procedure.
Fig. 3 a and b. A heart and kidney transplant patient on combined ciclosporin and
calcium channel blocker therapy. The marginal gingiva is infected and the gingival
papillae  have overgrown,  preventing normal dental care at home (a).  The over-
growth was removed surgically, dental calculus and bacterial films were removed,
and the patient was advised on proper dental care at home. b = after treatment.
Fig. 4 a and b. The patient was on felodipine therapy with gingival over-
growth. The patient also has periodontitis, an untreated infection of the periodon-
tium.  a = prior to treatment, b = after treatment.
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tal nurse, with maintenance treat-
ment at individually determined in-
tervals, which in some patients may
be as frequently as every couple of
months.
Transplant patients receiving ci-
closporine therapy should be given
antimicrobial prophylaxis in dental
treatment procedures which cause
haemorrhage.  Furthermore, when
antimicrobial treatment is planned
for a patient on ciclosporines, possi-
ble interaction between the antibiot-
ic and ciclosporine should be consid-
ered. Erythromycin, doxycycline and
fluconazole, for example, increase
the ciclosporin concentration in
plasma.
Cases have been reported in the
literature concerning the use of
azithromycin for the treatment of ci-
closporine-induced gingival over-
growth (26,27).  Azithromycin is a
macrolide antibiotic agent of the
azalide group. The agent is strongly
bound to the tissues ; pharmacoki-
netic studies have detected consider-
ably higher concentrations in tissue
than in the plasma. There are no
studies, however, of the interactions
of azithromycin and ciclosporine,
and consequently the circumstances
of treatment should be carefully
considered before these drugs are
used concurrently (10).
Summary
The pathogenesis of gingival over-
growth caused by ciclosporine, calci-
um channel blockers and phenytoin
is not known.  An interaction of sev-
eral varying factors is likely.  A com-
mon pointer for these drugs is that
they have an inhibiting effect on the
inflow of calcium ions into the cell
membrane. Alternative drugs are of-
ten not possible. The only remaining
alternative treatment is therefore
surgical removal of the gingival
overgrowth, treatment of the peri-
odontium, and careful self-treatment
at home, since the development of
overgrowth is encouraged by plaque
associated with poor oral hygiene
and the consequent inflammatory
changes.
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Acetylsalicylic acid (ASA), numbers
of combination preparations con-
taining ASA, and paracetamol have
traditionally been available in Fin-
land without a prescription (over-
the counter, OTC) for the treatment
of pain and fever. More recent anti-
inflammatory drugs, ibuprofen and
ketoprofen, have later been included
among these OTC drugs.  The con-
sumption of anti-inflammatory
drugs has been widely discussed.
OTC category has been expected to
boost the sales of the preparation
due, for instance, to improved avail-
ability and permitted marketing to
the general public. A survey has
been made of the effects that the
switch to OTC drugs has had on the
consumption of anti-inflammatory
drugs (1). In this article the figures
from the survey have been augment-
ed with the sales figures for 2000.
The target of the survey is the con-
sumption of anti-inflammatory anal-
gesics and paracetamol (DDD/1,000
inhabitants/day) during 1989–2000.
The range of anti-inflammatory
analgesics
The range of anti-inflammatory
analgesics available by prescription
in 1989 consisted of 17 drugs and
combinations of drugs. By the year
2000 only 13 of these remained in
use, and 7 new drugs and 2 new
combinations had been introduced
on to the Finnish market through
the years. The most recent additions
to the selection are the COX-2 selec-
tive anti-inflammatory drugs.
The range of OTC drugs has
been simplified in recent years. Anti-
inflammatory drugs available nowa-
days include ketoprofen and dex-
ibuprofen plain, and ASA, ibuprofen
and paracetamol both plain or as
combination preparations which al-
so include active ingredients such as
vitamin C, caffeine and/or an anti-
tussive. In association with renewals
of marketing authorisations for
analgesics in 1998 it was considered
that combination preparations con-
sisting of one or more ASA deriva-
tives or containing combinations of
codeine and caffeine were no longer
appropriate today in the light of
their efficacy and safety, and their
marketing authorisations were con-
sequently no longer renewed.
Ibuprofen and ketoprofen as OTC
drugs
The first OTC preparations of 200
mg ibuprofen in packages of 20
tablets were introduced on to the
market in 1987, and 400 mg ibu-
profen in 10-tablet packages was in-
troduced in June 1989.  Since OTC
preparations are mainly intended for
temporary use, the total amount of
ibuprofen in OTC packages is re-
stricted to 4 grams.  No special safe-
ty risks have been reported  from
the subsequent OTC use of ibupro-
fen.  In 2000, ibuprofen accounted
for 55% of the retail sale value, and
59% of the consumption, of OTC
analgesics.   
The introduction of ketoprofen
in an OTC status has been more
complicated. Small packages of ke-
toprofen 50 mg (15 capsules and 10
tablets) were brought on to OTC
market in September 1992.  Discus-
sions on the efficacy and safety of
ketoprofen in large doses were start-
ed soon afterwards.  As knowledge
about the use improved, it emerged
that, in many cases, a sufficient ef-
fect is reached with a single dose of
as little as 25 mg, and that the effi-
cacy is not significantly increased by
further increases in dose.  Increasing
the dose nevertheless increases the
adverse effects considerably (2).  It
was consequently considered inap-
propriate to retain the 50 mg
strength among the OTC range.  It
was transferred back to the POM-
category in July 1996, while small
packages of 25 mg ketoprofen re-
mained among the OTC drugs.
Total consumption of anti-inflam-
matory analgesics
The total consumption (DDD/1,000
inhabitants/day) of anti-inflammato-
ry analgesics during the  past 12
years has increased by 16% (OTC
drugs by 3% and prescription drugs
by 26%, Fig. 1).  The increase has
not been steady, but the consump-
tion has both decreased and in-
creased during the survey period.
Consumption of anti-inflammato-
ry prescription drugs
The biggest changes have occurred
in the consumption of ketoprofen
and ibuprofen (Fig. 2). The con-
sumption of ketoprofen peaked in
1994, totalling 11.86 DDD/1,000
inhabitants/day.  The consumption
has decreased since and totalled
5.07 DDD/inhabitants/day in 2000.
The increase in consumption of
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ibuprofen occurred towards the end
of the survey period.  It is the most
commonly used anti-inflammatory
analgesic in Finland at present.
The consumption of naproxen
increased steadily at the beginning
of the survey period and peaked
(9.12 DDD/1,000 inhabitants/day)
in 1996, when it was the most com-
monly used anti-inflammatory anal-
gesic.  Its use has since gradually de-
creased.
The consumption of paracetamol
has increased steadily since its mod-
est start. The consumption of nime-
sulide, introduced on to the market
in 1997, has increased sharply. Byt
2000 it was already the third most
commonly used anti-inflammatory
drug with consumption reaching
6.24 DDD/1,000 inhabitants/day.
The consumption of diclofenac
has remained steady during the en-
tire survey period. The consumption
of tolfenamic acid, indometacin and
piroxicam has decreased continuous-
ly. 
Consumption of OTC drugs
The consumption of OTC drugs has
increased by only 3% during the
past 12 years, and there has been a
concurrent switch in consumption
from combination preparations to
preparations consisting of only one
active substance. The consumption
of preparations containing one ac-
tive substance has increased by 29%
and the consumption of combina-
tion preparations has decreased by
65% (Fig. 3).
The biggest changes in the con-
sumption of OTC preparations are
found in the decreased consumption
of combination preparations and
ASA and in the increased consump-
tion of ibuprofen (Fig. 4).
ASA used to be the most com-
monly used analgesic in self-medica-
tion.  Its consumption has decreased
continuously during the last ten
years.  The consumption of ASA
(DDD/1,000 inhabitants/day) has
decreased by 62% in 12 years.  The
decrease has been steady except for
a rise which occurred in 1993.
The consumption of OTC prepa-
rations of ibuprofen has been con-
stantly on the increase. In 1995, its
consumption reached the level of
that of ASA and since 1996 it has
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Fig. 1.  Total  consumption of  anti - inf lammatory analgesics (DDD/1,000 in-
habitants/day).
Fig. 2. Consumption of  the most  common anti - inf lammatory prescr ipt ion
drugs (DDD/1,000 inhabitants/day).
Fig. 3.  Consumption of  OTC preparat ions (DDD/1,000 inhabitants/day).
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been the most commonly used anti-
inflammatory OTC drug (Fig. 4-5).
Ketoprofen became an OTC
drug in 1992.  At first, its consump-
tion increased greatly until 1993;  it
then dropped in 1994, and  a down-
ward trend began again in 1996
(Fig. 4 and 5).
What influences the choice of
drug?
A report based on an analysis of an
extensive literature survey states that
no significant differences can be
found in efficacy between the vari-
ous anti-inflammatory analgesics.
On the other hand, the profiles of
the adverse effects of the prepara-
tions differ more clearly from one
another (3). The use of anti-inflam-
matory analgesics is associated with
increased risk of GI bleeding. In has
been estimated that the incidence of
GI bleeding could decrease even by
70% if the NSAIDs with lowest risk
would be used (4). 
It could be assumed that the sig-
nificance of adverse effects would be
the key issue in the choice of drug.
When the bases for choice of drug
have been reviewed by classifying
anti-inflammatory analgesics into
low risk and high risk preparations
in view of their gastrointestinal ad-
verse effects, it has been found that
the choice of drug in Denmark, Italy
and Sweden varied between the
countries to such an extent that the
information compiled on adverse ef-
fects did not appear to control the
choice (5).In Finland, the present
consumption appears to favour anti-
inflammatory analgesics with lower
risk of GI bleeding.
The effect of the switch to 
OTC category
According to a report drawn up in
Sweden, switches to self-medication
made in 1980–1994 increased the
consumption of these drugs by an
average of 36% within two years of
the switch. There were nevertheless
large individual variations among
the drugs. Consumption of the same
drugs by prescription decreased by
26% at the same time (6). The re-
port dealt with all the preparations
which were switched to being avail-
able for self-medication, and was
not targeted, for example, at anal-
gesics. 
A study in the USA discussed the
effect of switching H2 blockers to
the OTC category  according to the
number of prescriptions issued. The
study found that the reduction in
the number of prescriptions of H2
blockers was statistically significant.
Nevertheless, the number of doctor’s
appointments arising from gastroin-
testinal diseases did not increase (7).
Indirectly, it could be assumed that
patients switched over to self-med-
ication as and when it became possi-
ble. The sales of H2 blockers by pre-
Fig. 4.  Consumption of  the most  common anti - inf lammatory OTC prepara-
t ions  (DDD/1,000 inhabitants/day).
Fig. 5.  Consumption of  ibuprofen and ketoprofen (DDD/1,000 inhabi-
tants/day) during 1984–2000.
Fig. 6.  Consumption of ketoprofen in individual doses during 1992–2000.
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scription were also reduced in Fin-
land when some containers were
switched to the OTC range of drugs
(8).
The consumption of prescription
packages of ibuprofen dropped at
the beginning of the 1990s, but
started an upward trend again in
1993.  This drop in consumption
was linked in time with the switch
of ibuprofen to self-medication.  It is
possible that the abolition of pre-
scription status robbed the prepara-
tion of some of its placebo effect
and doctors started prescribing oth-
er prescription preparations. This
may partly explain the increase in
prescribed consumption of ketopro-
fen detected at the same time.
The apparent increase in con-
sumption of ketoprofen in 1993 is
explained by the fact that in 1992
ketoprofen was sold as an OTC
drug for only part of the year. The
drop in 1994 can possibly be ex-
plained by the forceful marketing of
the new OTC drug to pharmacies
and consequent filling up of stocks
during 1993.  The stocks were still
being sold to customers during 1994
and were not replenished at the
same rate as that at which the drug
was changing hands and being re-
ceived by consumers.
The rapid increase in the con-
sumption of prescription packages
of ketoprofen moderated and it re-
mained steady during 1992–1994.
This recession in consumption oc-
curs at the same time as the switch
of small packages of ketoprofen to
the OTC range. This recession in
prescription drug consumption ap-
pears to have been similar to that re-
ported during the switch of ibupro-
fen to the OTC range of drugs.
Ketoprofen 50 mg preparations
were considered to be inappropriate
for OTC sales and they were conse-
quently returned to prescription on-
ly status in July 1996. These circum-
stances, and the discussion preced-
ing them, may have been the cause
of reduced popularity of ketoprofen.
A survey based on the values of
DDD/1,000 inhabitants/day gives a
somewhat misleading picture of the
switch back to prescription status of
the 50 mg packages. The consump-
tion (DDD/1,000 inhabitants/day)
dropped by 68% between 1995 and
2000.  Part of the drop is explained
by the reduction in consumption,
but part of it can be explained by
the shift to a lower strength.  Look-
ing at the number of sold doses
(tablets, capsules) in OTC use, the
drop has only been 27% (Fig. 6).
Subsequently, the number of drug
doses used in self-medication did not
drop as much as an examination of
the DDD values (150 mg) suggests.
The previously used strength of 50
mg in self-medication was replaced
by 25 mg.  The consumption and
sales of ketoprofen OTC have re-
mained fairly steady since 1996.
Conclusions
During the survey period, various
circumstances and factors associated
in particular with ketoprofen may
explain its present position on the
anti-inflammatory analgesic market.
Based on the information from this
survey alone, it is impossible to say
which factors have been decisive at
their respective points in time.  After
sharp rises and falls in sales figures
in the first years, ketoprofen appears
to have attained a steady sale in the
OTC market.
The sales and consumption of
ibuprofen have been characterised
by a constant upward trend. Its sales
as a prescription drug dropped
slightly only at the beginning of the
1990s.  This may have been associ-
ated with its switch to OTC use.
The situation changed thereafter and
ibuprofen is today the most com-
monly used anti-inflammatory anal-
gesic, both OTC and by prescrip-
tion. In OTC use, the consumption
has switched from ASA and its com-
bination preparations to ibuprofen.
In the light of the survey it can
be established that
• the total consumption of anti-
inflammatory analgesics has re-
mained fairly steady during the
entire survey period.
• switching from one drug to an-
other does occur. While ibupro-
fen has gained large popularity,
the use of other anti-inflamma-
tory drugs has decreased.
• the consumption is not auto-
matically increased by a switch
to OTC use, but consumption
is influenced by several factors.
This can be seen by examining
the curve of development of
sales of ketoprofen.
• a switch to OTC use appears at
least temporarily to diminish
the consumption of the drug by
prescription. 
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